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ABSTRACT
The significance of this study lies in its proposal to insert an 
appropriate provision into the Patents Act 1983 to embody the 
provisions of Article 31bis TRIPS Agreement. The methodology 
adopted in this study is library-based, and relies extensively on 
primary sources such as the Paris Convention, the TRIPS Agreement 
and the Patents Act 1983. This is further supported through secondary 
sources such as articles, books, websites and newspaper reports. 
The research question posed in this study aims to identify the most 
appropriate provision that should be incorporated into the Patents 
Act 1983 in addressing the public health flexibilities provided under 
Article 31bis. The purpose of this study is to demonstrate that Article 
31bis is best incorporated into the Patents Act 1983, under the right 
of the government mechanism rather than through the compulsory 
license mechanism. Furthermore, the scope of this study is limited 
to issues that address the abuse of monopoly, granted by the patent 
system, with respect to the dire needs of public health. Hence, this 
paper discusses the mechanisms that address the abuse of the patent 
system under Article 5(A) Paris Convention, Articles 31 and 31bis 
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TRIPS Agreement, the relevant corresponding provisions under 
the Patents Act 1983, and subsequently formulates new proposed 
amendments to Section 84 of the Patents Act 1983 to buttress the 
public health flexibilities provided under Article 31bis. The outcome 
of this study proposes that the provisions of Article 31bis should 
be incorporated into the Patents Act 1983 under the right of the 
government mechanism, by replacing the current Section 84 of the 
Patents Act 1983 with a newly proposed Section 84. 9-7 
Keywords: Article 31bis, compulsory licence (CL), Patents Act 
1983 (PA), rights of government (ROG), TRIPS Agreement. 
INTRODUCTION
According to Ricketson (1984)1, a patent is the monopolistic right 
bestowed upon the owner, to exploit his patented invention for a 
particular duration of time. The law of patent grants the owner of 
an invention, exclusive rights to the invention, by issuing  a patent. 
Generally, the patent system is designed to stimulate innovation by 
granting protection, for a certain period of time to the patentee, to 
monopolize the exploitation of the patented invention exclusively, 
without any competition from the same or similar invention in the 
market. Moreover, this system is beneficial to everyone because 
the law dictates the disclosure of information in exchange for the 
grant of the patent. This helps spread the technical knowledge for 
the betterment of all (Bainbridge, 2012, p. 394)2. All members of 
the Paris Convention for the Protection of Industrial Property 18833 
(Paris Convention) and the Agreement on Trade-Related Aspects of 
Intellectual Property Rights 19944 (TRIPS Agreement) are obliged 
to provide a patent regime in their domestic intellectual property 
1 Ricketson, S. (1984). The law of intellectual property. Sydney: The 
Law Book Company Limited.
2 Bainbridge, I. David. (2012). Intellectual property ( 9th ed.) Pearson 
Education Limited.
3 Paris Convention for the Protection of Industrial Property 1883 (as 
amended on September 28, 1979), entered into force on June 3, 1984. 
4 Agreement on Trade-Related Aspects of Intellectual Property Rights 
1994 came into effect on 1 January 1995. Malaysia has been  a member 
of this Agreement since 1 January 1995. 
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protection mechanism. Malaysia is a member of both the Paris 
Convention and the TRIPS Agreement. In Malaysia, patent rights 
are governed by the Patents Act 19835 (PA). The PA grants exclusive 
rights to the owners of the patent with respect to their inventions 
(Section 36 PA, 1983). 
Although the TRIPS Agreement stresses the obligation of members 
to protect intellectual property rights, it also stipulates that member 
countries should establish well-balanced guidelines that protect 
these rights so as to combat any abuse arising from the intellectual 
property rights, particularly when there is a necessity to protect issues 
relating to public health and nutrition (Article 8, TRIPS Agreement, 
1994). In adhering to good policy, law and governance, particularly 
with regards to patents, member countries must take aggressive steps 
to ensure a good balance of rights between patent owners as well as 
the advancement of public interest and national development goals 
(Azam, 2016, p.92)6. The most common approach governments 
employ to balance these rights is by introducing exemptions or 
exclusions to patent rights in their relevant intellectual property 
laws (Bagley, 2018, pp. 2480-2481)7. Another common method 
employed to balance these rights is through the implementation of 
compulsory licenses (CL). CL is a legal measure adopted by many 
governments against patent abuse, particularly in relation to public 
health crisis (Kyung-Bok, 2019)8. It is a legal measure because this 
mechanism is approved under Article 5(A) of the Paris Convention, 
and Articles 31 and 31bis of the TRIPS Agreement. CL is a crucial 
mechanism when dealing with health-sensitive issues surrounding 
the patent law (Armouti, 2018, p.383)9. Of particular  interest 
5  Patents Act 1983, (Act 291), enforced October 1, 1986.
6 Azam, M. (2016). The experiences of TRIPS-compliant patent law reform 
in Brazil, China, India and South Africa—Lessons for Bangladesh. In 
Intellectual property and public health in the developing world, 89-
148, Cambridge, UK: Open Book. Retrieved from http://www.jstor.org/
stable/j.ctt1d41dm1.10 
7 Bagley, M.A. (2018). The morality of compulsory licensing as an ac-
cess to medicines tool. Minnesota Law Review, 102(6), 2463-2496.  
8 Kyung-Bok Son. (2019). Importance of intellectual property system in 
attempting compulsory licensing of pharmaceuticals: A cross-sectional 
analysis. BMC, Globalization and Health, 15, 42. Retrieved October 
08, 2019 from MEDLINE Complete Database. https://doi.org/10.1186/
s12992-019-0485-7
9 Armouti, W. (2018). Grounds for compulsory licence with selected 
cases granted for pharmaceuticals. Tulane Journal of International and 
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is the Doha Declaration 2001 (currently known as Article 31bis 
TRIPS Agreement) that addresses the concern of the World Trade 
Organization (WTO) members, particularly the least developed 
countries (LDC), with regards to the supply and easy access to 
medicines. 
This study addresses the issues of the CL- embedded Article 31bis 
regarding public health flexibilities and recommends the most 
suitable provision that is required to be inserted into PA, to improve 
the leverage on public health flexibilities. Although the Paris 
Convention and the TRIPS Agreement use  the terminology CL to 
address the “legal infringement” issues dealt therein, in Malaysia 
CL is categorized into two different rights that are exercised by 
two different parties. The first category of CL is the right available 
under Part X of the PA, for application by any person in  certain 
circumstances, whereby this application is processed by the 
statutory body in charge of intellectual property in Malaysia, i.e. 
the Intellectual Property Corporation of Malaysia10 (MyIPO). Rights 
of Government (ROG) under Section 84 PA is the second category 
of CL, where  this right is usually invoked by the Government on 
grounds of national emergency, without the need for  an application 
by any party. These 2 provisions under the PA incorporate the 
relevant requirements under Article 5(A) of the Paris Convention 
and Article 31 of the TRIPS Agreement. However, the PA has not 
incorporated the provisions of the new Article 31bis of the TRIPS 
Agreement, which came into effect in January 2017. 
This study analyses the balance of rights between patents and 
public interest by examining the compulsory licensing mechanism 
envisaged under Article 5(A) of the Paris Convention, and Articles 
31 and 31bis of the TRIPS Agreement. Thereafter, the findings 
will be cross- referenced to the corresponding provisions in the 
PA, and ultimately identify the provisions in the PA that are most 
suitable to be incorporated into the new provisions of Article 31bis, 
in relation to public health flexibilities. This study will review the 
two different mechanisms provided under the PA and with the 
inclusion of Article31bis of the TRIPS Agreement, the public health 
Comparative Law, 26(2), 381-404.
10 Intellectual Property Corporation of Malaysia is a statutory body looking 
after intellectual property matters in Malaysia which was incorporated 
under the Intellectual Property Corporation of Malaysia Act 2002, (Act 
617), an Act which was enforced on March 3, 2003.
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flexibilities provided under this Article which allow  for the right of 
“legal infringement” on grounds of public health, will subsequently 
be vested with the Government under the ROG provision through 
the replacement of the current Section 84 of the PA with a newly 
proposed Section 84.
METHODOLOGY
This research adopts the  doctrinal legal research methodology. The 
research methodology is purely library-based, and is mainly reliant 
on primary sources of information such as the Paris Convention, 
TRIPS Agreement and the PA. This is further supported by secondary 
sources, namely textbooks, journals and websites of relevant 
authorities. The websites of certain authorities are important as the 
provisions of Article 31bis had stemmed from a string of events 
under the purview of such authorities , and therefore had been widely 
reported. The research is theoretical, analytical and exploratory; 
where  Article 5(A) of the Paris Convention, and Articles 31 and 
31bis of the TRIPS Agreement are analysed and scrutinized, and 
thereafter, cross-referenced to the PA. This study explores the 
suitability of Article31bis in relation to the PA and concludes that 
Malaysia should amend the ROG provision, i.e. Section 84 of the PA 
to incorporate the public health flexibilities provided under Article 
31bis by proposing an amended draft of a new Section 84 for the PA.
DISCUSSION
National policies on patents are often long-term policies that take 
into consideration various strategies that are based on economic, 
scientific and technological developments (Miyamoto, 2008, 
p.155)11. These policies are significantly important to public interest 
considerations which are based on normative, constitutional and 
11 Miyamoto, T.(2008). International treaties and patent laws harmoniza-
tion: today and beyond. Takenaka, T. (Ed.), Patent law: A handbook 
of contemporary research, (154-187). Cheltenham,UK: Edward Elgar 
Publishing. Retrieved from https://search-ebscohost-com.ezlib.iium.
edu.my/login.aspx?direct=true&db=nlebk&AN=265871&site=eds-
live.       
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philosophical justifications (Sitorus, 2016, p. 85)12. The issues of 
public interest are usually issues that are related to the balancing 
of rights between a patent owner and the public. Article 7 of 
the TRIPS Agreement requires an international public interest 
consideration, whereby member countries in ensuring “protection 
and enforcement of intellectual property, should contribute to the 
promotion of technological innovation” for the mutual benefits of 
“producers and users” in a manner that is “conducive to social and 
economic welfare”, and subsequently, to maintain a “balance of 
rights and obligations”. Prior to the TRIPS Agreement, balancing 
of these rights was  first incorporated into the Paris Convention via 
Article 5(A), whereby the mechanism used to prevent the abuse 
was expressly referred to therein as CL. The following sections will 
discuss the various provisions in the Paris Convention and the TRIPS 
Agreement concerning CL, and we will then make a cross-reference 
of these provisions to the corresponding provisions in the PA.  
Article 5(A) Paris Convention
 
Article 5(A) of the Paris Convention which is titled “Patents: 
Importation of Articles; Failure to Work or Insufficient Working: 
Compulsory Licenses” allowed members of the Union to incorporate 
legislative measures into their laws, to prevent abuse of patent 
rights which may arise due to monopoly rights granted to the 
patent holders. This can be achieved through the issuance of CL in 
appropriate cases. An example provided to illustrate such abuse is 
the failure to work the invention which has been patented (Article 
5(A)(2) of the Paris Convention, 1883 (Timble, 2016)13. “Failure to 
work” implies that the owner of an invention that has been granted 
a patent, had “failed to put into practice” his invention, within the 
country that issued the patent (Conteras, 2017, p 4)14. Article 5(A) 
12 Sitorus, W. (2016). Public interest in patent protection: The need of 
criteria. Journal of Law, Policy and Globalization, 45, 85-94.
13 See Timble, M. (2016). Patent working requirements: Historical and 
comparative perspectives. UC Irvine Law Review, 6(3), 483-508 for a 
better understanding on failure to work. 
14 Conteras, George L, Rohani Lakshane, Lewis, M. Paxton. ((2017). 
Patent working requirements and complex products. New York 
University Journal of Intellectual Property and Entertainment Law, 17, 
1-50.
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stipulates a specific condition in the application of a CL, whereby 
a CL application will not be entertained on grounds that a patentee 
has failed to work the invention which had  been patented, before the 
expiration of “4 years from the date of filing  the patent application 
or 3 years from the date the grant of the patent” was awarded, or 
whichever period expired  last (Article 5(A)(4) Paris Convention, 
1883). General terms and conditions to grant CL are also specified 
therein, however, CL cannot be granted if the owner “justifies his 
inaction with legitimate reasons”, and that the CL will be “non-
exclusive and non-transferrable” (Article 5(A)(4) Paris Convention, 
1883). There are many countries, for example Bahrain, Brazil, 
Chile, China and the Philippines (Visser, 2010, p.4)15, that have a 
CL provision in their patent system.
Malaysia, being a signatory of the Paris Convention since January 
1, 1989, has incorporated this mechanism of the CL under Part X 
PA which consists of Sections 48-54. CL, under Part X, is referred 
to as an authorization to perform in Malaysia, the act of exploiting 
an invention which has been patented, without the agreement of 
the patentee (Section 48 PA, 1983). Exploitation includes “making, 
importing, offering for sale, selling or using the patented product or 
stocking them for sales” purposes (Section 36(3)  PA, 1983). Under 
the PA, any person can apply for a CL from the Registrar of Patents, 
in the event that there is “no production of the patented product” 
in Malaysia, or there is no product for sale in Malaysia, or in some 
cases, the products are sold at unreasonable high prices without any 
legitimate reason. The application can only be made after attempts to 
obtain authorization from the patent owner has been futile (Section 
49 PA, 1983), or upon the expiration of the term of 4 or 3 years 
stated herein above. Although Article 5(A) of the Paris Convention 
does not specify the procedures with regards to a CL application, 
Part X of the PA clearly lays down the procedures that are required 
for the application for a CL, such as the amount of royalty and 
conditions for exploitation (Section 50  PA, 1983). A CL application 
15 Coenrad Visser. (2010).  Patent exceptions and limitations in the health 
context, SCP/15/3 - Experts study on exclusions from patentable subject 
matter and exceptions and limitations to the rights. World Intellectual 
Property Organization. SCP/16/REF/SCP/15/3. Annex V. Retrieved 
October 13, 2019 from https://www.wipo.int/edocs/mdocs/scp/en/
scp_16/scp_16_ref_scp_15_3-annex5.pdf.
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in Malaysia is considered and decided upon by MyIPO. The CL 
provisions under Part X stems from the provisions of Article 31 of 
the TRIPS Agreement. Such requirements for CL are the efforts that 
are needed to be undertaken to obtain the patentee’s approval first, 
and the grant of CL can only be given for the supply of the patented 
product into the local market. The requirements in Article 31 herein 
will be further discussed in the following section.
The concise provisions regarding CL under Part X of the PA are 
solid and comply  with Article 5(A) of the Paris Convention, and 
the decision to grant CL being vested in MyIPO, is indeed the 
correct approach chosen by the Malaysian Government. MyIPO is 
the statutory body that is in charge of intellectual property matters 
and is capable of assessing the reasons to grant a CL to an applicant 
in accordance to Part X, as the issues involved must be within the 
Malaysian territory. For this reason, the verification of information 
about these situations in the event that an issue arises may be 
easily obtained through investigations carried out by MyIPO. The 
availability of CL under the PA is important to Malaysia because 
being a developing country, balancing of rights between the patent 
owners and the public is indeed of utmost importance (Arega, 
2019, p. 31)16. Thus far, there has been no application for a CL to 
MyIPO. Although issues relating to high prices of medicines had 
arisen in Malaysia, particularly medication for HIV and Hepatitis C, 
the provisions of CL under Part X of the PA were never put to use 
as no third party or generic manufacturers had applied to MyIPO 
for a CL to combat these rising prices. Therefore, to address these 
health problems, the Government invoked the ROG as can be seen 
in the following part. Hence, till today, MyIPO has no experience in 
dealing with issues in respect of the issuance of CL.    
         
Article 31 TRIPS Agreement
Article 31 is titled “Other Use without Authorization of the Right 
Holder”. Article 31 allows  members to accommodate a provision in 
their laws allowing the use of an invention which has been patented, 
without acquiring consent from the patentee. This right was granted 
mainly to three parties; “a third party”, “the government”, or “other 
16 Arega, M. (2019). Defending local working. American University 
Intellectual Property Brief, 10(2), 28-61.
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parties that are authorized by the government”, where  this right is 
subjected to certain rules17. Article 31 is a continuation of Article 30. 
Article 30 gives an option to member countries “to provide limited 
exceptions to the exclusive rights conferred by a patent, provided 
that such exceptions do not unreasonably conflict with the normal 
exploitation of the patent” in issue (Guan, 2016, pp. 423-424)18. 
Article 31 “gives permission” to third parties to use the invention 
that has been granted a patent, without the consent of the patentee, 
for reasons other than those provided under Article 30. Although 
Article 31 makes no reference to the term CL, it is nevertheless 
commonly referred to as the “CL provision” (Effingham, 2016, 
pp. 883-909; Raducanu, 2011; WTO; World Health Organization 
[WHO])19. This is supported by the stringent rules that need to be 
17 An example  of such rules is the authorization of the use shall be based 
on individual merits and there shall be a right of judicial review of such 
authorization; the use is only authorized should efforts made to obtain 
the patentee’s authorization  had been futile. This rule is exempted in 
situations of national emergency, other circumstances of extreme urgency 
or in cases of public non-commercial use. Nevertheless, in such cases, 
the patentee shall be informed of this use as soon as possible.; the scope 
and duration of the use shall be limited to the purpose it was authorized 
The use shall be non-exclusive; the use shall be non-assignable; the 
use shall be predominantly for the supply of the  local market only; 
the use shall be subject to adequate protection of the legitimate interest 
of the party so given the authorization and such authorization can be 
terminated when the reason for the authorization given, had ceased. 
The patentee is paid adequate remuneration for the use and issues 
related to adequacy shall be subject to judicial review; and for purposes 
of remedying a practice determined as anti-competitive. The use need 
not be subjected to the rule of obtaining the approval of the patentee 
first and the rule to supply for the domestic market only.
18 Guan, W. (2016). IPRs, public health, and international trade: An 
international law perspective on the TRIPS amendment. Leiden Journal 
of International Law, 29(2), 411-440. An example of an exception to 
patent right is that rights of patents are  only for commercial purposes 
and do  not cover acts done solely for scientific purpose. This limitation 
of right is provided under the PA in Section 37.  
19 Effingham, Ann Marie. (2016). TRIPS Agreement Article 31(b): The 
need for revision. Seton Hall Law Review, 46, no.3, 883-909; Raducanu, 
Adina.(2011).  Who is afraid of compulsory licences. USAK Yearbook 
of International Policy & Law, 4, 255-288;  World Trade Organization. 
(n.d.). Compulsory licensing of pharmaceuticals and TRIPS. Retrieved 
UUMJLS 11(2), July 2020 (1-26)
10
adhered to which are listed out therein when exercising this right 
of “legal infringement”. Article 31 is not a mandatory provision as 
it offers member countries the choice to adopt and establish this 
system.
Malaysia, being a signatory to the TRIPS Agreement since 1995, has 
opted to use this system and has incorporated the provisions into the 
PA. Most of the rules and provisions stated in Article 31 have been 
incorporated into Part X PA. Hence, Part X consists of a combination 
of Article 5(A) of the Paris Convention and Article 31 of the TRIPS 
Agreement (only to the extent where this system is used by a third 
party). Subsequently, when “a Government or a party authorized by 
the Government” uses this system, the PA defines this utilization as the 
“Rights of Government”, which has been specifically incorporated 
into Section 84. The PA clearly distinguishes CL from ROG. CL is 
applied by a third party strictly on grounds that are specified under 
Article 5(A) of the Paris Convention and under Part X of the PA, 
whereas ROG is invoked by the Government for the application of 
the system by “the Government or a third party that is authorized by 
the Government” on two specific grounds. Firstly, ROG is invoked 
in the event of “national emergency” or “public interest”, such as 
“national security and health” issues (Article 31(b)). Secondly, it is 
granted when “a judicial or relevant authority has determined” that 
the patent owner had exploited his invention in an “anti-competitive” 
manner, (Article 31(c)). Although Article 31 does not distinguish 
between CL and ROG,  the PA has demarcated these rights into two 
categories of rights that are used by different parties. This allows 
for a much simpler and clearer determination of rights to ensure an 
appropriate balance of rights between patent owners and the public20. 
Issues involving abuse of patent rights within the local territory is 
governed by MyIPO, while matters involving national interests are 
regulated by the Government. The ROG, under Section 84 of the 
PA, can only be invoked by the Minister of Domestic Trade and 
July 22, 2019, from https://www.wto.org/english/tratop_e/trips_e/
public_health_ faq_e.htm; and World Health Organization. (n.d). The 
Doha Declaration on the TRIPS Agreement and public health. Retrieved July 22, 
2019, from https://www.who.int/medicines/areas/policy /policy/doha_declaration/en/.
20 See Ali, F. (2016). Nexavar: The first market-initiated compulsory 
licence. NUJS Law Review, 9(2), 229-258, for further understanding 
on difference between a government use CL (ROG in Malaysia) and 
market-initiated CL (CL in Malaysia).
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Consumer Affairs (DTCA), as the ministry is in charge of matters 
relating to intellectual property, upon determination by the Cabinet, 
i.e. the Government, on either of the events specified above (Section 
84(1) PA). Moreover, until such a determination has been made by 
the Government, the Minister of DTCA has no right to invoke the 
ROG.
Malaysia has invoked the ROG mechanism twice, initially in 2004 
to address the HIV issue, and once again in 2017 to address the 
Hepatitis C issue in Malaysia. However, the invocation of this 
right under ROG was commonly mistaken to be an issuance of 
CL21. Taking into account the 2 different mechanisms of CL and 
ROG that exist under the PA, this study focuses on clarifying this 
misconception and then goes on to suggest the incorporation of 
Article 31bis of the TRIPS Agreement into the PA by the inserting 
a new proposed Section 84 PA. The detailed substantive provisions 
on ROG as envisaged under the current Section 84 of the PA are 
rigorous and fit the purpose of Articles 31(b) and 31(c) of the TRIPS 
Agreement. The decision to place the invocation of ROG under the 
purview of the Government has indeed been the correct approach 
chosen by the Malaysian Government. The Minister of DTCA is 
in a strong and capable position to deal with the implications of 
a national emergency and public interest situation as he is part of 
the Cabinet and is able to understand the situation comprehensively 
(Ahmad, 2012)22. As the Minister is in charge of intellectual property 
matters under the current legal system, he will be able to exercise his 
rights accordingly under the PA by taking into account the national 
agenda. 
21 See Foley, E. (2019). Predicting the 2019 301 Special Report. Creighton 
International and Comparative Law Journal, 10(1), 87-101; Third 
World Network. (2017, November 3). Sharing national experiences 
in use of compulsory licences. Retrieved September 10, 2019, from 
https://www.twn.my/title2/intellectual_property/info.service/2017/
ip171102.htm; and Report: Cabinet approves compulsory licence for 
Hepatitis C generics. (2017, September 14). The Malay Mail. Retrieved 
September 10, 2019, from https://www.malaymail.com/news/
malaysia/2017/09/14/report-cabinet-approves-compulsory-license-for-
hepatitis-c-generics/1464619.  
22 Ahmad Masum. (2012). The doctrine of ministerial responsibility 
in Malaysia: Theory and practice in a new regime of parliamentary 
accountability. Malayan Law Journal Article, 4, clv-clxxvi.
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Article 31bis TRIPS Agreement
Article 31bis is the newly inserted provision of the TRIPS Agreement, 
which was enforced in January 2017. It embodies the effort of the 
members of the WTO in recognising the need of a system to help 
the poorer member countries to gain easier access to medicine 
(Alsegard, 2004)23. Article 31bis clearly refers to the system 
envisaged therein as CL and provides flexibility to “countries with 
insufficient or inexistent manufacturing capabilities” to produce the 
pharmaceutical products which have been granted patents, without 
first obtaining the permission of the patentee, and this can be done 
strictly on reasons of public health flexibilities. Member countries 
of the WTO finally recognized this concern, particularly the need 
of those in the least developed countries (LDC) to have access to 
medicines through imports from other countries (WTO)24. The LDC 
lack the manufacturing capabilities, and therefore, these countries 
are not able to produce medicines to cater for their public health 
concern. Consequently, Article 31bis was introduced to allow CL 
to be invoked, whereby generic medicines can be made and there 
is no need to obtain authorization from the patentee to do this. The 
generic versions are then exported by the exporting member country 
to the LDC which are the eligible importing countries (Houston, 
2019, pp. 232-233)25. This is the main objective of Article 31bis. 
Many countries such as Canada, Norway and Netherlands have 
begun amending their  patent legislation since the Doha Declaration 
2003 (Abbot & Van Pyumbroeck, 2005, pp. 2-3)26  which embodies 
23 Alsegard, Erik. (2004).  Global pharmaceutical patents after the Doha 
Declaration – What lies in the future. SCRIPTed:  A Journal of Law, 
Technology and Society, 12, 12-45. 
24 World Trade Organization (n.d).  TRIPS and public health.  Retrieved 
July 22, 2019, from https://www.wto.org/english/tratop_e/trips_e /
pharmpatent_e.htm.  
25 Houston, A. R., & Beall, R. F (2018). Could the paragraph compulsory 
licence system be revised to increase participation by the generics in-
dustry:  Lessons learned from unheralded and unsuccessful attempt to 
use Canada’s access to medicines regime. McGill Journal of Law and 
Health, 12, 227-246.
26 Abbot, F. M., & Van Pyumbroeck, R.V.(2005). Compulsory licensing 
for public health  A guide and model documents for implementation 
of the Doha Declaration Paragraph 6 decision. World Bank Working 
Paper No. 61. Retrieved from http://documents.worldbank.org/curated/
en/173701468337882214/pdf/334260rev0pub.pdf.  
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the decision of Paragraph 6 therein, and has now been incorporated 
into Article 31bis. 
It is indeed disheartening to note that as of 2019, the PA does 
not have a provision on the public health flexibilities provided 
by Article 31bis despite Malaysia being involved in “the Doha 
Declaration on TRIPS and Public Health” since 2001. Malaysia 
also accepted the “Protocol Amending the TRIPS Agreement” in 
December 2015 (WTO). It has been more than 2 years since this 
Protocol was enforced, however, Malaysia is yet to incorporate 
these flexibilities into the PA. As a developing country, Malaysia 
must address the global call on affordable access to medicines. As 
far as Malaysia is concerned, this call envisaged under Article 5(A) 
of the Paris Convention and Article 31 of the TRIPS Agreement has 
been implemented by incorporating the provisions on CL and ROG 
into the PA. However, the policy, law and governance in managing 
the country, especially with regards to public health concerns, must 
be expanded to benefit the less fortunate countries, particularly the 
LDC, through the integration of the provisions of Article 31bis into 
the PA. 
RECOMMENDATIONS
Whilst the patent system’s integrity must be enforced accordingly, 
it is simply just right for the public to have access to affordable 
medications, particularly in times of crisis involving public health 
(Halterman, 2018, p. 511)27. Therefore, this study proposes that 
Malaysia incorporates the provisions of Article 31bis into the PA by 
amending Section 84 to grant the Malaysian Government the right 
to expand the benefit it has provided to its citizens and to include 
the citizens of other lower income countries. Furthermore, the 
implementation of this mechanism will ensure adequate remuneration 
to the patent owner and provide assurances that the right will be 
exercised prudently and meticulously by the sovereignty of the 
country, based on the given situation. Invocation of the ROG would 
be the most appropriate mechanism to be adopted by Malaysia for 
27 Halterman, C. (2018). Patent rights v public access: Interpreting the 
public interest factor in pharmaceutical patent infringement cases. 
Southern Illinois University Law Journal, 42(3), 499-520. 
UUMJLS 11(2), July 2020 (1-26)
14
purposes of Article 31bis, as the Government is in the best position 
to monitor recent developments within the global community. In 
addition, the ability of the Government to assess the need of other 
sovereign countries, in relation to the access of medicines, would 
eliminate any potential abuse of the public health flexibilities as 
cautioned under paragraph (4) Annex to Article 31bis. 
A CL system under Part X would be inappropriate in such scenarios 
as the time and costs may be significantly expended, particularly 
since it is a pre-condition that a person seeking a CL must have first 
taken steps to ensure that he has attempted to obtain the consent 
of the patentee. This action alone will take time and would lead to 
unnecessary delays in putting into effect the main aim of Article 
31bis. In addition, there is a possibility that the documents involved 
in the implementation of Article 31bis may require authentication. 
MyIPO, being the statutory body in charge of CL in Malaysia, 
may need verification from the Government on the authenticity of 
the documents submitted, and this may take more time. This was 
observed when Canada had access to the medicine regime through 
the CL system and was corresponding with the Canadian Intellectual 
Property Office in handling the application. However, it took 15 
months before supply could be given to Rwanda during the crisis in 
2007 due to the long processing time (Anderson, 2010, p. 180)28. This 
suggests that a CL system is an inappropriate system for the purposes 
of Article 31bis. Many African countries such as Namibia, Zanzibar 
and Botswana have incorporated this system into their legislations, 
whereby this right lies with their Ministers (Banda, 2016, p. 71)29. 
Envisaging the rights under Article 31bis at the Ministerial levels 
would be the most appropriate measure to address the issues related 
to Article 31bis. Essentially, when a sovereign country uses this 
right, it captures the attention of the international community, hence, 
ensuring a good monitoring system of use under Article 31bis. 
28 Anderson, B. (2010). Better access to medicines. Why countries are 
getting tripped up and not ratifying Article 31-bis. Case Western Reserve 
Journal of Law, Technology and the Internet, 1(2), 165-182. 
29 Banda, C. (2016). Intellectual property and access to essential 
pharmaceuticals: Recent law and policy reforms in the Southern Africa 
development community region. Maryland Journal of International 
Law, 31, 44-78.
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Based on the above reasons, in order to ensure the elimination 
of abusive practices of the system under Article 31bis, this study 
proposes that the right to invoke this system should be placed under 
the purview of the Malaysian Government as a ROG pursuant to 
Section 84 of the PA, and not under the CL system pursuant to Part X 
of the PA. Furthermore, this study suggests substituting the existing 
Section 84 of the PA, with a new Section 84, whereby the current 
provision on ROG pursuant to Article 31 of the TRIPS Agreement 
is expanded to include the flexibilities provided under Article 31bis. 
The new proposed Section 84 is set out here below where  only the 
amended provisions are shown without much repetition of the existing 
provisions. The current existing Section 84 of the PA is reproduced 
in the Appendix, for ease of comparison and identification of the 
relevant amendments proposed to be made thereto. 
“Section 84. Rights of Government.  
(1) Notwithstanding ……- 
 (a) ………………; 
 (b) ………………; 
 (c) where there is a request made by an  
 eligible importing country, to the  
 Government for the manufacture  
 of a pharmaceutical product to address  
 an epidemic issue in its country, and the  
 Government agrees to such a request;  
 or 
 (d) where there is an epidemic problem  
 in respect of public health in Malaysia  
 and the Government decides to import  
 a pharmaceutical product from an  




(3) Where invocation of the rights by the Minister 
is pursuant to: -
 (a) paragraph  (1)(c), the Government shall  
 notify the Council for TRIPS of all  
 relevant information regarding the  
 exportation of the pharmaceutical  
 product; and 
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 (b) paragraph  (1)(d), the Government shall  
 notify the Council for TRIPS of all  
 relevant information regarding the  
 importation of the pharmaceutical  
 product. 
(4) The exploitation of the patent under this 
section shall be limited to the purpose for 
which it was authorized and shall be subject 
to payment to the owner of the patent of an 
adequate remuneration for such exploitation, 
taking into account:
 (a) the economic value of the Minister’s  
 authorization as determined in the  
 decisions under paragraphs 1(a) and  
 1(d);
 
(b) where a decision has been taken  
 under paragraph (1)(b), the need to  
 correct anticompetitive practices; and
 (c) where a decision has been taken under  
 paragraph (1)(c), the economic value  
 to the eligible importing country of the  
 use that has been authorized by the  
 Minister.   
(5) Notwithstanding subsection (4), in the event 
the Minister’s authorization under this section 
is pursuant to paragraph (1)(d), the Minister 
shall not be required to pay any remuneration 
to the owner of the pharmaceutical product 
in Malaysia, in the event the owner of the 
pharmaceutical product had been paid 
remuneration in the exporting country.
(6) The Minister shall make his decision under 
subsection (4) after hearing the owner of the 
patent and any other interested person, if they 
wish to be heard.
(7) …….. (the current subsection (5)).
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(8) …….. (the current subsection (6)).
(9) …….. (the current subsection (7)).  
(10) The exploitation of the patent by the Government 
agency or the third person designated by the 
Minister shall be predominantly for the supply 
of the market in Malaysia:
 Provided always that this paragraph shall not 
be applicable in the event the exploitation by 
the Government agency or the third person 
designated by the Minister, is made pursuant 
to an authorization issued in accordance with 
paragraph (1)(c). 
(11) Upon the request of:-
 (a) the owner of the patent; 
 (b) the Government agency or the third  
 person authorized to exploit the patent;  
 or 
 (c) the eligible importing country, 
 the Minister may, after hearing the relevant 
parties, if they wish to be heard, vary the terms 
of the decision authorizing the exploitation 
of the patent, to the extent that the changed 
circumstances justify such variation, provided 
always that, for changes involving a situation 
which concerns paragraph (c) of subsection 
(1), the Government shall notify the Council 
for TRIPS, of such changes. 
(12) …….. (the current subsection 10)).
  
(13) Notwithstanding subsection (12), the Minister 
shall not terminate the authorization if he is 
satisfied that the need for adequate protection 
of the legitimate interests of the Government 
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agency or the third person designated by him 
justifies the maintenance of the decision.  
(14) ….. (the current subsection (12).  
(15) In this section-
 “Council for TRIPS” means the body 
responsible for administering the TRIPS 
Agreement under the World Trade 
Organization;
 “eligible importing country” means any 
least-developed country or any other member 
country of the TRIPS Agreement that has 
made a notification to the Council for TRIPS 
of its intention to make a request to import 
a pharmaceutical product, in accordance 
with Article 31bis and Annex of the TRIPS 
Agreement;
 “exporting country” means a TRIPS 
Agreement member country which produces 
pharmaceutical products for and exports 
them, to Malaysia;
 “Government agency” means the Federal 
Government or the Government of a State 
and includes a Ministry or Department of that 
Government; 
 “patented invention” means any invention 
that has been patented in accordance with this 
Act and includes pharmaceutical products;
 “pharmaceutical  product”  means  any   patented 
product, or product manufactured through 
a patented process, of the pharmaceutical 
sector including but not limited to the active 
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ingredients necessary for its manufacture and 
diagnostic kits needed for its use, which is 
required to address an epidemic problem;
 “TRIPS Agreement” means the Agreement on 
Trade-Related Aspects of Intellectual Property 
enforced on January 1, 1995 including any 
amendments thereto.”  
The proposed amendments embodied in the above new Section 84 of 
the PA will grant the Government various flexibilities in invoking the 
provisions of Article 31 and Article 31bis, under a single provision 
in the PA. 
CONCLUSION
Malaysia is indeed a TRIPS compliant member country and has set up 
a good legal protection mechanism for the enforcement of intellectual 
property rights. Although Malaysia highly respects and encourages 
the security of intellectual property, it has always attempted to strike 
a fair balance between the intellectual property rights owner and the 
wider interest of the public, particularly in respect of the law relating 
to patents. This requirement of balance for patent rights is enshrined 
in Article 5(A) of the Paris Convention and Articles 31 and 31bis 
of the TRIPS Agreement. These provisions allow governments to 
exercise some flexibilities, should there be abuse of patent rights. It is 
a human’s right to have a right to healthcare, and there is no doubt that 
having easy access to medicines is also an embodied right. Malaysia 
garnered international attention when it provided easy access to 
medicines to Malaysians when the country was faced with public 
health problems in 2004 and 2017, signifying Malaysia’s approach 
to the balance of rights while protecting intellectual property rights 
through the invocation of the ROG mechanism pursuant to Section 
84 of the PA. Malaysia should fully endorse the new Article 31bis, 
particularly for supporting the LDC , by incorporating a provision 
into the PA to address the issue therein. 
The incorporation of this Article into Section 84 of the PA under 
the ROG mechanism, would uphold the Government’s sovereign 
UUMJLS 11(2), July 2020 (1-26)
20
position and concern towards public health issues, in the eyes of 
the world, since it is the Government itself that will be handling 
this issue directly and not merely an agency of the Government 
(MyIPO). It is proposed that the flexibilities under Article 31bis 
of the TRIPS Agreement be carried out via the ROG mechanism 
under Section 84 of the PA, and not the CL mechanism under Part 
X of the PA, because it shows the Government’s sovereign hands-
on approach when dealing with public health issues concerning its 
citizens and its country, as well as the rest of the world. In addition, 
the current Article 31 of the TRIPS Agreement provisions in respect 
of interference of patents on grounds of security and public health 
issues for use in domestic situations, are already embedded in  the 
ROG mechanism under Section 84 of the PA. Therefore, it is simply 
prudent and logical that for purposes of Article 31bis (incorporated 
into the TRIPS Agreement pursuant to the provisions of Article 31 
specially to address issues relating to public health crisis only, which 
includes the right of the country to now export the pharmaceutical 
products for use outside its country), these rights be inserted into 
the ROG mechanism under Section 84 of the PA and not the CL 
mechanism under Part X of the PA. 
Suggestions of incorporating the flexibilities provided under Article 
31bis of the TRIPS Agreement into Part X of the PA (if any), would 
set a double standard in the Government’s approach towards public 
health crisis, whereby for issues of public health in its country, the 
sovereign decides, but for the public health crisis in other countries, 
a mere organization in charge of intellectual property viz. MyIPO 
would be the decision- maker. This double standard would not make 
Malaysia look good in the eyes of the world as Malaysia has always 
been recognized by the world as a champion for its efforts with 
regards to public health matters, both nationally and internationally. 
This great concern of “always being there and playing an important 
role during a public crisis situation” shown by Malaysia, can be 
evidenced based on Malaysia’s public health- related actions taken 
in 2004 and 2017 and more so important, now, in 2020, where 
Malaysia is playing an active role by implementing hands-on actions 
in addressing the current Covid-19 pandemic, when it was one of 
the first few countries in the world to implement the “lockdown” 
mechanism, by introducing the Movement Control Order in its 
effort of curbing the pandemic. Malaysia’s actions which are being 
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carried out gracefully and calmly, is not only for the benefit of the 
Malaysians themselves but also for the benefit of the world at large. 
This shows that Malaysia places utmost importance on issues 
relating to public health and as such, for purposes of Article 31bis 
of the TRIPS Agreement, the most appropriate mechanism is the 
ROG mechanism, which allows the Government of Malaysia to 
exercise the public health flexibilities and not the CL mechanism 
under the purview of an agency viz. MyIPO. Both the world at large, 
particularly the LDC , as well as Malaysians, stand to benefit from 
this proposal of envisaging Article 31bis of the TRIPS Agreement 
into Section 84 of the PA, as it is the sovereign of the state with 
access to all information in hand, that will immediately decide 
on a public health crisis, whether be it a crisis at the national or 
international level.    
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Appendix
“Section 84 Patents Act 1983. Rights of Government.
(1) Notwithstanding anything contained in this Act - 
 (a) where there is national emergency or where the 
  public interest, in particular, national security, 
  nutrition, health or the development of other vital 
  sectors of the national economy as determined by the 
  Government, so requires; or 
 (b)  where a judicial or relevant authority has determined 
 that the manner of exploitation by the owner of the 
 patent or his licensee is anti-competitive, the Minister 
 may decide that, even without the agreement of the 
 owner of the patent, a Government agency or a third 
 person designated by the Minister may exploit a 
 patented invention. 
(2) The owner of the patent shall be notified of the decision of the 
 Minister as soon as is reasonably practicable. 
(3) The exploitation of the patented invention shall be limited to 
 the purpose for which it was authorized and shall be subject to 
 the payment to the owner of the patent of an adequate 
 remuneration for such exploitation, taking into account - 
 (a) the economic value of the Minister’s authorization as 
  determined in the decision; and 
 (b) where a decision has been taken under paragraph (1) 
  (b), the need to correct anti-competitive practices. 
(4) The Minister shall make his decision under subsection (3) 
 after hearing the owner of the patent and any other interested 
 person if they wished to be heard. 
(5)  The exploitation of a patented invention in the field of 
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 semi-conductor technology shall only be authorized either -  
 (a) for public non-commercial use; or 
 (b) where a judicial or relevant authority has determined 
  that the manner of exploitation of the patented invention, 
  by the owner of the patent or his licensee, is anti- 
  competitive and if the Minister is satisfied that the 
  authorization would remedy such anti-competitive 
  practice. 
(6) The authorization shall not exclude - 
 (a) the continued exercise by the owner of the patent of his 
  rights under subsection 36(1); or 
 (b) the issuance of compulsory licences under Part X. 
(7) Where a third person has been designated by the Minister, the 
 authorization may only be transferred with the goodwill or 
 business of that person or with that part of the goodwill or 
 business in which the patented invention is being exploited.
(8) The exploitation of the invention by the Government agency or 
 the third person designated by the Minister shall be 
 predominantly for the supply of the market in Malaysia. 
(9) Upon the request of - 
 (a) the owner of the patent; or 
 (b) the Government agency or the third person authorized 
  to exploit the patented invention, 
the Minister may, after hearing the parties, if either or both 
wish to be heard, vary the terms of the decision authorizing 
the exploitation of the patented invention to the extent that 
changed circumstances justify such variation. 
(10) Upon the request of the owner of the patent, the Minister 
 shall terminate the authorization if he is satisfied, after hearing 
 the parties, if either or both wish to be heard, that the 
 circumstances mentioned in subsection (1) which led to his 
 decision have ceased to exist and are unlikely to recur or that 
 the Government agency or the third person designated by him 
 has failed to comply with the terms of the decision. 
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(11) Notwithstanding subsection (10), the Minister shall not 
 terminate the authorization if he is satisfied that the need for 
 adequate protection of the legitimate interests of the 
 Government agency or the third person designated by him 
 justifies the maintenance of the decision. 
(12) The owner of a patent, a Government agency or the third 
 person authorized to exploit a patented invention may appeal 
 to the Court against the decision of the Minister under this 
 section. 
(13) In this section “Government agency” means the Federal 
 Government or the Government of a State and includes a 
 Ministry or Department of that Government.”
